JP7193476B2 - 組換えヒト酸性アルファグリコシダーゼ - Google Patents

組換えヒト酸性アルファグリコシダーゼ Download PDF

Info

Publication number
JP7193476B2
JP7193476B2 JP2019562390A JP2019562390A JP7193476B2 JP 7193476 B2 JP7193476 B2 JP 7193476B2 JP 2019562390 A JP2019562390 A JP 2019562390A JP 2019562390 A JP2019562390 A JP 2019562390A JP 7193476 B2 JP7193476 B2 JP 7193476B2
Authority
JP
Japan
Prior art keywords
rhgaa
mol
atb200
subject
potential
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019562390A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020519638A5 (enExample
JP2020519638A (ja
Inventor
フン ドー，
ラッセル ゴッシャル，
リッチ カンナ，
イー ルン，
ヒング チャー，
セルゲイ テスラー，
ウェンディ サンダーランド，
エンリケ ディローン，
Original Assignee
アミカス セラピューティックス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アミカス セラピューティックス インコーポレイテッド filed Critical アミカス セラピューティックス インコーポレイテッド
Publication of JP2020519638A publication Critical patent/JP2020519638A/ja
Publication of JP2020519638A5 publication Critical patent/JP2020519638A5/ja
Priority to JP2022196057A priority Critical patent/JP2023051927A/ja
Application granted granted Critical
Publication of JP7193476B2 publication Critical patent/JP7193476B2/ja
Priority to JP2024170113A priority patent/JP2025016455A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0102—Alpha-glucosidase (3.2.1.20)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2019562390A 2017-05-15 2018-05-15 組換えヒト酸性アルファグリコシダーゼ Active JP7193476B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022196057A JP2023051927A (ja) 2017-05-15 2022-12-08 組換えヒト酸性アルファグリコシダーゼ
JP2024170113A JP2025016455A (ja) 2017-05-15 2024-09-30 組換えヒト酸性アルファグリコシダーゼ

Applications Claiming Priority (19)

Application Number Priority Date Filing Date Title
US201762506561P 2017-05-15 2017-05-15
US201762506569P 2017-05-15 2017-05-15
US201762506574P 2017-05-15 2017-05-15
US62/506,574 2017-05-15
US62/506,561 2017-05-15
US62/506,569 2017-05-15
US201762529300P 2017-07-06 2017-07-06
US62/529,300 2017-07-06
US201762564083P 2017-09-27 2017-09-27
US62/564,083 2017-09-27
US201762567334P 2017-10-03 2017-10-03
US62/567,334 2017-10-03
US201862618021P 2018-01-16 2018-01-16
US62/618,021 2018-01-16
US201862624638P 2018-01-31 2018-01-31
US62/624,638 2018-01-31
US201862660758P 2018-04-20 2018-04-20
US62/660,758 2018-04-20
PCT/US2018/032815 WO2018213340A1 (en) 2017-05-15 2018-05-15 Recombinant human acid alpha-glucosidase

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022196057A Division JP2023051927A (ja) 2017-05-15 2022-12-08 組換えヒト酸性アルファグリコシダーゼ

Publications (3)

Publication Number Publication Date
JP2020519638A JP2020519638A (ja) 2020-07-02
JP2020519638A5 JP2020519638A5 (enExample) 2021-07-26
JP7193476B2 true JP7193476B2 (ja) 2022-12-20

Family

ID=64274660

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019562390A Active JP7193476B2 (ja) 2017-05-15 2018-05-15 組換えヒト酸性アルファグリコシダーゼ
JP2022196057A Withdrawn JP2023051927A (ja) 2017-05-15 2022-12-08 組換えヒト酸性アルファグリコシダーゼ
JP2024170113A Pending JP2025016455A (ja) 2017-05-15 2024-09-30 組換えヒト酸性アルファグリコシダーゼ

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022196057A Withdrawn JP2023051927A (ja) 2017-05-15 2022-12-08 組換えヒト酸性アルファグリコシダーゼ
JP2024170113A Pending JP2025016455A (ja) 2017-05-15 2024-09-30 組換えヒト酸性アルファグリコシダーゼ

Country Status (25)

Country Link
US (2) US12246062B2 (enExample)
EP (2) EP3624831B1 (enExample)
JP (3) JP7193476B2 (enExample)
KR (2) KR102787774B1 (enExample)
CN (3) CN119113091A (enExample)
AU (2) AU2018270925B2 (enExample)
BR (1) BR112019024125A2 (enExample)
CA (1) CA3063615A1 (enExample)
CL (1) CL2019003251A1 (enExample)
DK (1) DK3624831T5 (enExample)
ES (1) ES2950808T3 (enExample)
FI (1) FI3624831T3 (enExample)
HR (1) HRP20230576T1 (enExample)
HU (1) HUE062504T2 (enExample)
IL (2) IL270530B2 (enExample)
LT (1) LT3624831T (enExample)
MX (3) MX2019013624A (enExample)
PL (1) PL3624831T3 (enExample)
PT (1) PT3624831T (enExample)
RS (1) RS64301B1 (enExample)
SI (1) SI3624831T1 (enExample)
SM (1) SMT202300187T1 (enExample)
TW (2) TWI870336B (enExample)
WO (1) WO2018213340A1 (enExample)
ZA (1) ZA201907552B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102618519B1 (ko) 2016-03-30 2023-12-28 아미쿠스 세라퓨틱스, 인코포레이티드 재조합 산 알파-글루코시다제를 포함하는 제형
CA3019354A1 (en) 2016-03-30 2017-10-05 Amicus Therapeutics, Inc. Method for selection of high m6p recombinant proteins
AU2018281280B2 (en) 2017-06-07 2024-12-19 Regeneron Pharmaceuticals, Inc. Compositions and methods for internalizing enzymes
CN112040985A (zh) 2018-02-07 2020-12-04 瑞泽恩制药公司 用于递送治疗性蛋白质的方法和组合物
EP3793591A1 (en) 2018-05-17 2021-03-24 Regeneron Pharmaceuticals, Inc. Anti-cd63 antibodies, conjugates, and uses thereof
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
EP3871687A1 (en) * 2020-02-27 2021-09-01 eleva GmbH Enzyme replacement therapy for treating pompe disease
JP2024506346A (ja) * 2021-02-11 2024-02-13 アミカス セラピューティックス インコーポレイテッド 組換えヒト酸性アルファグルコシダーゼ及びその使用
CN114280182A (zh) * 2021-12-23 2022-04-05 福建省中医药科学院 一种太子参均一多糖的hplc-fld检测方法
WO2023150387A1 (en) * 2022-02-07 2023-08-10 M6P Therapeutics, Inc. Compositions comprising acid alpha glucosidase and methods of use thereof
WO2023215865A1 (en) * 2022-05-05 2023-11-09 Amicus Therapeutics, Inc. Methods for treating pompe disease
AR131256A1 (es) * 2022-12-02 2025-03-05 Amicus Therapeutics Inc Métodos para tratar la enfermedad de pompe de inicio tardío en pacientes pediátricos
WO2024119091A1 (en) * 2022-12-02 2024-06-06 Amicus Therapeutics, Inc. Fexamethods for treating infantile-onset pompe disease in pediatric patients
WO2026004963A1 (ja) * 2024-06-26 2026-01-02 三菱ケミカル株式会社 分離材、分離材の製造方法、標的分子の分離方法、混合物、及びクロマトグラフィー用カラム

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150352042A1 (en) 2013-01-09 2015-12-10 Amicus Therapeutics, Inc. Stable parenteral dnj compositions
WO2016054231A1 (en) 2014-09-30 2016-04-07 Amicus Therapeutics, Inc. Highly potent acid alpha-glucosidase with enhanced carbohydrates

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4837237A (en) 1985-07-09 1989-06-06 Fred Hutchinson Cancer Research Center Therapy using glucosidase processing inhibitors
US5879680A (en) 1987-12-23 1999-03-09 The United States Of America As Represented By The Department Of Health And Human Services Cloned DNA for synthesizing unique glucocerebrosidase
US4985445A (en) 1988-02-12 1991-01-15 Meiji Seika Kaisha, Ltd. Cancer cell metastasis inhibitors and novel compounds
US6451600B1 (en) 1989-12-22 2002-09-17 Genzyme Corporation Enzymatically active recombinant glucocerebrosidase
US5236838A (en) 1988-12-23 1993-08-17 Genzyme Corporation Enzymatically active recombinant glucocerebrosidase
US5179023A (en) 1989-03-24 1993-01-12 Research Corporation Technologies, Inc. Recombinant α-galactosidase a therapy for Fabry disease
US5011829A (en) 1989-06-02 1991-04-30 G. D. Searle & Co. Pharmaceutical composition and method of inhibiting virus
US5103008A (en) 1989-08-17 1992-04-07 Monsanto Company Compound, N-butyl-deoxynojirimycin-6-phosphate
US5401650A (en) 1990-10-24 1995-03-28 The Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of biologically active α-galactosidase A
US5399567A (en) 1993-05-13 1995-03-21 Monsanto Company Method of treating cholera
US6118045A (en) 1995-08-02 2000-09-12 Pharming B.V. Lysosomal proteins produced in the milk of transgenic animals
US20020013953A1 (en) 1995-08-02 2002-01-31 Reuser Arnold J. Compositions and methods for treating enzyme deficiency
US20020073438A1 (en) 1995-08-02 2002-06-13 Reuser Arnold J. Methods of purifying human acid alpha-glucosidase
US6458574B1 (en) 1996-09-12 2002-10-01 Transkaryotic Therapies, Inc. Treatment of a α-galactosidase a deficiency
US6083725A (en) 1996-09-13 2000-07-04 Transkaryotic Therapies, Inc. Tranfected human cells expressing human α-galactosidase A protein
US6210666B1 (en) 1997-10-21 2001-04-03 Orphan Medical, Inc. Truncated α-galactosidase A to treat fabry disease
JP2001522833A (ja) 1997-11-10 2001-11-20 ジー・ディー・サール・アンド・カンパニー 多剤耐性を治療するためのアルキル化イミノ糖類の使用
US6465488B1 (en) 1997-12-11 2002-10-15 Chancellor, Masters & Scholars Of The University Of Oxford Inhibition of glycolipid biosynthesis
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
DK2020438T3 (en) 1998-12-07 2018-07-23 Genzyme Corp Treatment of Pompe disease
ES2311921T3 (es) 1999-02-12 2009-02-16 United Therapeutics Corporation N-(8,8,8-trifluorooctil)1-5,-didesoxi-1,5-imino-d-glucitol para tratar infecciones por el virus de la hepatitis.
JP2003505430A (ja) 1999-07-26 2003-02-12 ジー・ディー・サール・アンド・カンパニー デオキシノジリマイシンの長鎖ｎ−アルキル誘導体およびグルコセレブロシダーゼ酵素の糖脂質異常蓄積疾患の治療用の薬剤の製造のための使用
US6534300B1 (en) 1999-09-14 2003-03-18 Genzyme Glycobiology Research Institute, Inc. Methods for producing highly phosphorylated lysosomal hydrolases
US20020095135A1 (en) 2000-06-19 2002-07-18 David Meeker Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
US20040204379A1 (en) 2000-06-19 2004-10-14 Cheng Seng H. Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
US7056712B2 (en) 2000-07-18 2006-06-06 Duke University Treatment of glycogen storage disease type II
CN1638739A (zh) 2000-08-18 2005-07-13 法玛西雅厄普约翰美国公司 治疗成瘾性障碍的化合物
US7001994B2 (en) 2001-01-18 2006-02-21 Genzyme Corporation Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins
US7723296B2 (en) 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
EP1436316B1 (en) 2001-04-30 2008-01-23 ZyStor Therapeutics , Inc. Subcellular targeting of therapeutic proteins
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
CN1604788B (zh) 2001-10-16 2013-04-17 里克斯金蒂克斯公司 高浓度蛋白制剂及其制备方法
US20030072761A1 (en) 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
US7658916B2 (en) 2002-04-05 2010-02-09 Genzyme Corporation Methods of enhancing lysosomal storage disease therapy by modulation of cell surface receptor density
JP5589165B2 (ja) 2003-01-31 2014-09-17 マウント シナイ スクール オブ メディシン オブ ニューヨーク ユニバーシティー タンパク質欠損性障害の治療のための併用療法
FR2861991B1 (fr) 2003-11-07 2008-01-18 Centre Nat Rech Scient Utilisation d'inhibiteurs de glucosidase pour une therapie de la mucoviscidose
US20080014188A1 (en) 2004-02-06 2008-01-17 Zankel Todd C Manufacture of Highly Phosphorylated Lysosomal Enzymes and Uses Thereof
DE602005020745D1 (de) 2004-02-10 2010-06-02 Zystor Therapeutics Inc Saure alpha-glukosidase und fragmente davon
US20060142234A1 (en) 2004-12-23 2006-06-29 Guohua Chen Injectable non-aqueous suspension
EP3782655A1 (en) 2005-05-17 2021-02-24 Amicus Therapeutics, Inc. A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives
AU2007322123A1 (en) 2006-11-13 2008-05-29 Biomarin Pharmaceutical Inc. Methods for treating Pompe disease
CN102978185B (zh) 2007-01-18 2015-02-11 建新公司 包含氨基氧基基团的寡糖及其轭合物
EP2155197A4 (en) 2007-03-09 2011-10-12 Link Medicine Corp TREATMENT OF LYSOSOMAL STORAGE DISEASES
AU2008245578A1 (en) 2007-04-26 2008-11-06 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
US20100317690A1 (en) 2007-11-21 2010-12-16 Summit Corporation Plc Treatment of protein folding disorders
WO2009075815A1 (en) 2007-12-07 2009-06-18 Duke University Immunomodulating gene therapy
WO2009102895A2 (en) 2008-02-12 2009-08-20 Amicus Therapeutics, Inc. Method to predict response to pharmacological chaperone treatment of diseases
AU2009223125A1 (en) 2008-03-12 2009-09-17 Amicus Therapeutics, Inc. Assays for diagnosing and evaluating treatment options for Pompe disease
JP2011512876A (ja) 2008-03-12 2011-04-28 アミカス セラピューティックス インコーポレイテッド 特異的薬理シャペロンを用いたポンペ病の治療および代理マーカーを用いた治療の監視
WO2009137721A2 (en) 2008-05-07 2009-11-12 Zystor Therapeutics, Inc. Lysosomal targeting peptides and uses thereof
US20110237538A1 (en) 2008-08-06 2011-09-29 Summit Corporation Plc Treatment of lysosomal storage disorders and other proteostatic diseases
WO2010056746A1 (en) 2008-11-11 2010-05-20 Amicus Therapeutics, Inc. Therapy regimens, dosing regimens and stable medicaments for the treatment of pompe disease
EP3608330B1 (en) 2008-12-16 2022-11-09 Genzyme Corporation Synthetic intermediates for preparing oligosaccharide-protein conjugates
WO2010096369A1 (en) 2009-02-18 2010-08-26 Amicus Therapeutics, Inc. Mouse model for pompe disease and methods of use thereof
JP5645918B2 (ja) 2009-04-09 2014-12-24 アミカス セラピューティックス インコーポレイテッド リソソーム蓄積障害の予防および／または治療方法
EP2435459B1 (en) 2009-05-26 2016-05-04 Amicus Therapeutics, Inc. Utilization of pharmacological chaperones to improve manufacturing and purification of acid beta-glucosidase
US8785168B2 (en) 2009-06-17 2014-07-22 Biomarin Pharmaceutical Inc. Formulations for lysosomal enzymes
KR102000383B1 (ko) 2009-09-29 2019-07-15 유니버시테이트 젠트 만노스-1-포스포-6-만노스 결합의 포스포-6-만노스로의 가수분해
US9427033B2 (en) 2009-12-16 2016-08-30 Under Armour, Inc. Athletic arm warmer
US20130196410A1 (en) 2010-03-05 2013-08-01 Alnylam Pharmaceuticals, Inc Compositions and methods for modifying the glycosylation pattern of a polypeptide
BR112013007616B1 (pt) 2010-09-29 2023-01-24 Oxyrane Uk Limited Métodos para retirar o cap ("uncapping") de porções de manose-1- fosfo-6-manose e desmanosilar n-glicanos fosforilados em uma glicoproteína, para direcionar uma glicoproteína para o interior de uma célula de mamífero, e para converter uma glicoproteína de uma primeira forma que não se liga substancialmente a um receptor de manose-6-fosfato em uma segunda forma que se liga substancialmente a um receptor de manose-6-fosfato em uma célula de mamífero
SG10201605874TA (en) 2011-04-22 2016-09-29 Genzyme Corp Modified acid alpha glucosidase with accelerated processing
WO2013013017A2 (en) 2011-07-21 2013-01-24 Alnylam Pharmaceuticals, Inc. Compositions and methods for modifying the glycosylation of lysosomal storage disorder therapeutics
JP6180423B2 (ja) * 2011-11-08 2017-08-16 ユニヴァーシティ オブ ワシントン リソソーム酵素アッセイ法および組成物
WO2013091897A1 (en) 2011-12-22 2013-06-27 Centogene Gmbh Combination of a compound having the ability to rearrange a lysosomal enzyme and ambroxol and/or a derivative of ambroxol
KR20200032244A (ko) 2012-03-07 2020-03-25 아미쿠스 세라퓨틱스, 인코포레이티드 폼페병의 치료를 위한 고농도 알파-글루코시다제 조성물
CA2867237C (en) 2012-03-15 2024-01-02 Wouter Vervecken Methods and materials for treatment of pompe's disease
RS61598B1 (sr) * 2012-05-03 2021-04-29 Amicus Therapeutics Inc Režimi doziranja za tretman pompeove bolesti
US20150147309A1 (en) 2012-06-06 2015-05-28 Fondazione Telethon Allosteric chaperones and uses thereof
PT3086784T (pt) 2013-12-23 2019-06-27 Bcn Peptides Sa Análogos de bicalutamida ou (s)-bicalutamida como compostos ativadores de exocitose para utilização no tratamento de um distúrbio de armazenamento lisossómico ou glicogenose
WO2017049161A1 (en) * 2015-09-18 2017-03-23 Duke University ACID ALPHA-GLUCOSIDASE AND A β-2 AGONIST FOR THE TREATMENT OF LYSOSOMAL STORAGE DISORDER
IL299470B2 (en) * 2015-12-30 2026-05-01 Amicus Therapeutics Inc Improved acid alpha-glucosidase for the treatment of Pompe disease
CA3019354A1 (en) 2016-03-30 2017-10-05 Amicus Therapeutics, Inc. Method for selection of high m6p recombinant proteins
KR102618519B1 (ko) 2016-03-30 2023-12-28 아미쿠스 세라퓨틱스, 인코포레이티드 재조합 산 알파-글루코시다제를 포함하는 제형

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150352042A1 (en) 2013-01-09 2015-12-10 Amicus Therapeutics, Inc. Stable parenteral dnj compositions
WO2016054231A1 (en) 2014-09-30 2016-04-07 Amicus Therapeutics, Inc. Highly potent acid alpha-glucosidase with enhanced carbohydrates

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
A Novel Recombinant Human Acid Alpha-Glucosidase, ATB200, Leads to Greater Substrate Reduction and Improvement in Pompe Disease-Relevant Markers Compared to Alglucosidase Alfa in Gaa KO Mice，13th Annual WORLDSymposium, 2017.2, [retrieved on 2022/02/17]，<https://www.amicusrx.com/app/uploads/2017/11/150102332-07_WORLD-2017-n-vivo-poster-YL_FINAL.pdf>
Anal. bioanal. Chem., 2017.1, Vol.409, No.2, pp.453-466
Molecular Genetics and Metabolism, 2016, Vol.120, p.S42, #74
POMPE PHASE 1/2 STUDY (ATB200-02) PRELIMINARY DATA CONFERENCE CALL & WEBCAST，[ONLINE]，AMICUS THERAPEUTICS，2016年12月08日，P1-13，https://ir.amicusrx.com/static-files/4670f216-8974-472a-afd9-19f307291b06

Also Published As

Publication number Publication date
DK3624831T3 (da) 2023-06-26
PL3624831T3 (pl) 2023-08-14
EP3624831A1 (en) 2020-03-25
HUE062504T2 (hu) 2023-11-28
AU2025203557A1 (en) 2025-06-05
LT3624831T (lt) 2023-07-10
CA3063615A1 (en) 2018-11-22
KR20200004414A (ko) 2020-01-13
IL270530B1 (en) 2024-03-01
ES2950808T3 (es) 2023-10-13
IL310719A (en) 2024-04-01
EP3624831B1 (en) 2023-03-29
JP2023051927A (ja) 2023-04-11
TWI870336B (zh) 2025-01-21
CN119113091A (zh) 2024-12-13
CL2019003251A1 (es) 2020-05-22
JP2020519638A (ja) 2020-07-02
WO2018213340A1 (en) 2018-11-22
EP4223310A3 (en) 2023-10-11
MX2019013624A (es) 2020-01-13
AU2018270925A1 (en) 2019-11-28
ZA201907552B (en) 2024-09-25
SMT202300187T1 (it) 2023-07-20
PT3624831T (pt) 2023-07-04
BR112019024125A2 (pt) 2020-06-02
CN119139461A (zh) 2024-12-17
AU2018270925B2 (en) 2025-02-20
TW201900208A (zh) 2019-01-01
US20210393747A1 (en) 2021-12-23
US20250057925A1 (en) 2025-02-20
TW202448499A (zh) 2024-12-16
JP2025016455A (ja) 2025-02-04
RS64301B1 (sr) 2023-07-31
EP3624831A4 (en) 2021-02-17
FI3624831T3 (fi) 2023-06-12
MX2024015740A (es) 2025-02-10
IL270530B2 (en) 2024-07-01
KR20250044950A (ko) 2025-04-01
KR102787774B1 (ko) 2025-04-01
SI3624831T1 (sl) 2023-08-31
DK3624831T5 (da) 2024-09-02
EP4223310A2 (en) 2023-08-09
CN111356474A (zh) 2020-06-30
IL270530A (en) 2020-01-30
MX2024015741A (es) 2025-02-10
HRP20230576T1 (hr) 2023-09-01
US12246062B2 (en) 2025-03-11

Similar Documents

Publication Publication Date Title
US20250057925A1 (en) Recombinant Human Acid Alpha-Glucosidase
JP7046003B2 (ja) 高ｍ６ｐ組換えタンパク質の選択方法
WO2020163480A1 (en) Recombinant human acid alpha-glucosidase and uses thereof
JP2024506346A (ja) 組換えヒト酸性アルファグルコシダーゼ及びその使用
US20260041744A1 (en) Methods for Treating Pompe Disease
EA045409B1 (ru) Рекомбинантная человеческая кислая альфа-глюкозидаза
HK40026823B (en) Recombinant human acid alpha-glucosidase
HK40026823A (en) Recombinant human acid alpha-glucosidase
CN117157095A (zh) 重组人类酸性α-葡萄糖苷酶和其用途
BR122024026309A2 (pt) Alfa-glicosidase ácida humana recombinante
HK40032702A (en) Recombinant human acid alpha-glucosidase

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210514

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210514

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220224

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220308

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220601

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220802

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220908

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221108

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221208

R150 Certificate of patent or registration of utility model

Ref document number: 7193476

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250